Cabaletta Bio Statistics
Share Statistics
Cabaletta Bio has 50.74M
shares outstanding. The number of shares has increased by 1.24%
in one year.
| Shares Outstanding | 50.74M |
| Shares Change (YoY) | 1.24% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 78.6% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,058 |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 6.1M, so 12.48% of the outstanding
shares have been sold short.
| Short Interest | 6.1M |
| Short % of Shares Out | 12.48% |
| Short % of Float | 12.89% |
| Short Ratio (days to cover) | 10.79 |
Valuation Ratios
The PE ratio is -0.97 and the forward
PE ratio is -0.68.
Cabaletta Bio's PEG ratio is
-0.02.
| PE Ratio | -0.97 |
| Forward PE | -0.68 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 0.74 |
| P/FCF Ratio | -1.24 |
| PEG Ratio | -0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cabaletta Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.15,
with a Debt / Equity ratio of 0.1.
| Current Ratio | 6.15 |
| Quick Ratio | 6.15 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.17 |
| Interest Coverage | 167.3 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-719,652.17 |
| Employee Count | 161 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -83.48% in the
last 52 weeks. The beta is 2.72, so Cabaletta Bio's
price volatility has been higher than the market average.
| Beta | 2.72 |
| 52-Week Price Change | -83.48% |
| 50-Day Moving Average | 1.41 |
| 200-Day Moving Average | 3.04 |
| Relative Strength Index (RSI) | 74.98 |
| Average Volume (20 Days) | 1,110,974 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -125.14M |
| Net Income | -115.86M |
| EBITDA | -125.14M |
| EBIT | -116.61M |
| Earnings Per Share (EPS) | -2.37 |
Full Income StatementBalance Sheet
The company has 163.96M in cash and 15.6M in
debt, giving a net cash position of 148.36M.
| Cash & Cash Equivalents | 163.96M |
| Total Debt | 15.6M |
| Net Cash | 148.36M |
| Retained Earnings | -349.1M |
| Total Assets | 165.14M |
| Working Capital | 100.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -88.22M
and capital expenditures -2.21M, giving a free cash flow of -90.43M.
| Operating Cash Flow | -88.22M |
| Capital Expenditures | -2.21M |
| Free Cash Flow | -90.43M |
| FCF Per Share | -1.83 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
